key: cord-0851775-4mfkya1n
authors: Lee, Hyun; Choi, Hayoung; Lee, Sun-Kyung; Park, Tai Sun; Park, Dong Won; Moon, Ji-Yong; Kim, Tae-Hyung; Sohn, Jang Won; Yoon, Ho Joo; Kim, Sang-Heon
title: Predicting Factors of Severe COVID-19 in Patients With Asthma: A Korean National Cohort Study
date: 2021-05-13
journal: Allergy Asthma Immunol Res
DOI: 10.4168/aair.2021.13.6.939
sha: 0275977b70dd1c962ba2f0b821b1e93c87bfb849
doc_id: 851775
cord_uid: 4mfkya1n

As there are limited data on the disease course of and factors predicting severe coronavirus disease 19 (COVID-19) in patients with asthma, this study aims to perform a detailed analysis of the clinical course of asthmatic patients with COVID-19 and evaluate factors related to severe infection. Of the 5,628 patients confirmed with COVID-19, 128 (2.3%) had asthma. Among the 128 asthmatic patients, 32 (25%) had severe COVID-19 and 96 (75%) had non-severe COVID-19. Among asthmatic patients, those with severe COVID-19 were significantly older and had more dyspnea and fever, more comorbidities, and lower lymphocyte and platelet counts than those with non-severe COVID-19. In multivariable logistic regression analysis, chronic obstructive pulmonary disease (adjusted odds ratio [aOR], 6.49; 95% confidence interval [CI], 1.18–41.81), low lymphocyte proportion (aOR, 0.91; 95% CI, 0.86–0.97), and low platelet count (aOR, 0.99; 95% CI, 0.98–0.99) were independently associated with severe COVID-19.

The infection caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is called coronavirus disease 2019 (COVID-19), has spread rapidly worldwide since December 2019. 1 The prevalence of asthma in patients with COVID-19 ranges from 0.9% to 15% in different studies, 2,3 which denotes the conflicting evidence regarding asthma patients' susceptibility to COVID-19. It seems that some important factors link asthma and the severe clinical course of COVID-19 1, 4 ; however, little information is available regarding this issue. Accordingly, we sought to perform a detailed analysis of the clinical course of asthmatic patients with COVID-19 and evaluate factors associated with severe COVID-19.

The Korea Disease Control and Prevention Agency (KDCA) provided researchers with an anonymized national cohort of 5,628 patients with confirmed COVID-19, who had Dong Won Park https://orcid.org/0000-0002-4538-6045 Ji-Yong Moon https://orcid.org/0000-0003-2459-3448 Tae-Hyung Kim https://orcid.org/0000-0002-3863-7854 Jang Won Sohn https://orcid.org/0000-0001-7132-2988 Ho Joo Yoon https://orcid.org/0000-0002-4645-4863 Sang-Heon Kim https://orcid.org/0000-0001-8398-4444

There are no financial or other issues that might lead to conflict of interest.

completed treatment or quarantine as of April 30, 2020. 5 This cohort comprised information on demographics, symptoms at the time of hospitalization, vital signs, comorbidities, laboratory findings, treatment (supplemental oxygen, mechanical ventilation, and extracorporeal membrane oxygenation), and treatment outcomes including death. The institutional review board of our institution approved this study (application No. HYUH 2020-07-035). Since the KDCA cohort data were constructed after anonymization, the need for informed consent from the participants was waived.

Laboratory confirmation of SARS-CoV-2 infection was defined as a positive result on a realtime reverse-transcriptase polymerase chain reaction assay of nasal or pharyngeal swabs, following the Guidelines for Laboratory Diagnosis of COVID-19 in Korea. 6 Asthma diagnosis was based on the patient reporting physician-diagnosed asthma. Fever was defined as a body temperature of ≥ 37.5°C, and hypotension was defined as a systolic blood pressure of < 120 mmHg or a diastolic pressure of < 80 mmHg. Severe COVID-19 was defined based on the treatment level during hospitalization: cases requiring supplemental oxygen therapy via nasal prong or facial mask, non-invasive/invasive mechanical ventilation, or extracorporeal membrane oxygenation treatment in addition to those who died after a confirmed COVID-19 diagnosis. Accordingly, COVID-19 cases presenting dyspnea at the time of hospitalization but not requiring supplemental oxygen were classified as non-severe COVID-19. Continuous variables are presented as mean ± standard deviation and compared using Student's t test or Mann-Whitney U test, as appropriate. Categorical variables are presented as number (%) and compared using the chi-squared test or Fisher's exact test, as appropriate. To evaluate factors associated with severe COVID-19, we performed univariable and multivariable analyses. In multivariable analyses, age, sex, and significant factors in univariable analysis were included.

During the study period, all patients who had confirmed COVID-19 were isolated in hospitals or residential treatment centers according to the policy of the KDCA. Of the 5,628 patients, 128 (2.3%) had asthma. Among the 128 asthma patients, 32 (25.0%) had severe COVID-19 and 96 (75.0%) had non-severe COVID-19. Of the 32 severe COVID-19 patients, 40.6% (n = 13) died. Severe COVID-19 patients were significantly more likely to be aged ≥ 60 years (71.9% vs. 37.5%, P < 0.001) than non-severe COVID-19 patients; however, there were no intergroup differences in sex and body mass index. Regarding symptoms at the time of hospitalization, severe COVID-19 patients had a significantly higher rate of fever (37.5% vs. 16.7%, P = 0.014) and dyspnea (46.9% vs. 21.9%, P = 0.006) than non-severe COVID-19. Additionally, in terms of comorbidities, severe COVID-19 patients showed a significantly higher rate of chronic obstructive pulmonary disease (COPD) (15.6% vs. 4.2%, P = 0.043), heart failure (9.4% vs. 0%, P = 0.015), and malignancies (9.4% vs. 0%, P = 0.015) than non-severe COVID-19. On laboratory findings, lymphocyte proportion (18.3% ± 9.9% vs. 29.2% ± 10.7%, P < 0.001) and platelet count (199.8 ± 67.9 vs. 264.3 ± 86.6, P < 0.001) were significantly lower in severe COVID-19 than non-severe COVID-19 ( 

The presented findings showed a natural course of asthmatic patients with COVID-19 and factors associated with a severe presentation. Approximately one-fourth of asthmatic patients with COVID-19 experienced severe disease requiring at least oxygen supplementation, of whom approximately 40% died. We further showed comorbid COPD was independently associated with a severe presentation.

As previous studies focused more on whether asthma is associated with poor outcomes in COVID-19, 3, 7 few studies addressed factors associated with the severe presentation of COVID-19 in asthmatic patients. Although studies revealed that recent use of oral corticosteroid and nonallergic asthma are associated with severe disease course, 8 these studies did not provide detailed information on symptoms, comorbidities, or laboratory findings. 1, 4 One major advantage of our study is that we used nationwide data including initial clinical characteristics of all COVID-19 patients at the time of diagnosis. Accordingly, we evaluated demographic factors, symptoms, comorbidities, and laboratory findings and showed that co-existing COPD and baseline lymphocyte proportion and platelet count are independently associated with increased risk of severe COVID-19. This is in line with previous reports showing that COPD patients are at increased risk of severe pneumonia and poor outcomes when they develop COVID-19. 9 942 https://e-aair.org https://doi.org/10.4168/aair.2021.13.6.939 Asthmatic patients with COPD were more likely to have a history of smoking and taking more medications, including systemic corticosteroids, while they had fewer allergic symptoms, 10 which are associated with severe COVID-19. In addition, in agreement with a previous report, 11 low lymphocyte proportion and platelet count were independently associated with severe COVID-19 in asthmatic patients. The lymphopenia can be explained by detrimental effects of the inflammatory cytokine milieu plus a direct attachment of lymphocytes to the vascular wall, known as endotheliitis. 11 Additionally, thrombocytopenia may be indicative of coagulopathy observed in patients with severe COVID-19. 11 There are limitations to this study. First, we lacked information on current asthma treatment such as inhaled corticosteroid use since the KDCA database does not provide such data. Although a recent study showed that regular inhaled corticosteroid (ICS) therapy was not associated with either increased or decreased risk of mortality, 7 further studies are needed to determine whether ICS use has a protective effect against the development of severe COVID-19. Second, because there is no definite consensus on the definitions of severe COVID-19, and symptoms that influence the treatment levels are thought to be clinically relevant; we determined to classify severe COVID-19 based on the treatment level. However, there might be different opinions on the classification of severe COIVID-19. For example, patients with high fever or change in consciousness can be regarded as having severe COVID-19. Third, we could not decide whether dyspnea in each patient results from asthma alone or asthma plus COVID-19 as the KDCA database did not provide information about this issue. Fourth, the number of asthmatic patients was relatively small, which might explain the lack of significance in multivariable analyses (e.g., age, dyspnea, and fever). Future studies enrolling a large number of patients are needed.

In conclusion, among asthmatic patients, those with severe COVID-19 were significantly older, had more dyspnea and fever, more comorbidities including COPD, heart failure, and malignancies, and lower lymphocyte proportion and platelet count than those with nonsevere COVID-19. Of these, COPD, low lymphocyte proportion, and low platelet count were independently associated with severe COVID-19.

Clinical characteristics of coronavirus disease 2019 in China

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Asthma among hospitalized patients with COVID-19 and related outcomes

Factors associated with COVID-19-related death using OpenSAFELY

Cheongju: Korea Disease Control and Prevention Agency; c2021

Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Association of asthma and its genetic predisposition with the risk of severe COVID-19

COVID-19 and COPD

Characteristics of specialist-diagnosed asthma-COPD overlap in severe asthma: observations from the Korean Severe Asthma Registry (KoSAR)

Immune reactivity during COVID-19: implications for treatment